Nanoparticules ultrafines en radiothérapie : le cas des AGuIX

Lux, François; Detappe, Alexandre; Dufort, Sandrine; Sancey, Lucie; Louis, Cédric; Carme, S. C.; Tillement, Olivier

doi:10.1016/j.canrad.2015.05.019

Cited by 9 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such modelling has been performed after irradiation at 80 keV ( Figure 7 ). 57 The clustering of a few gadolinium atoms leads to the formation of an Auger shower inducing a strong increase of the deposited dose close to the gadolinium cluster. However, more theoretical studies are needed to more clearly determine the exact mechanism of action of AGuIX NPs in association with RT.…”

Section: Radiosensitizationmentioning

confidence: 99%

“…In particular, the radiosensitizing effects of AGuIX NPs on clinical irradiators at 6 MV have been demonstrated in a number of cell lines including cervical carcinoma – HeLa (incubation at [Gd 3+ ] = 0.5 mM) (SER 4Gy = 1.3; Dose Enhancement Factor (DEF) = 1.2), 57 glioblastoma–U87MG (SER from 1.10 to 1.50 for concentrations ranging from 0.1 to 0.5 mM) 58 and pancreatic adenocarcinoma–panc1 (DEF = 1.30) (incubation at [Gd 3+ ] = 0.5 mM) ( Figure 8 ). 46 , 59 The DEF is the ratio of the area between the survival curves with and without NPs.…”

Section: Radiosensitizationmentioning

confidence: 99%

See 1 more Smart Citation

AGuIX^® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine

Lux

Tran

Thomas

et al. 2018

BJR

110

108

View full text Add to dashboard Cite

AGuIX are sub-5 nm nanoparticles made of a polysiloxane matrix and gadolinium chelates. This nanoparticle has been recently accepted in clinical trials in association with radiotherapy. This review will summarize the principal preclinical results that have led to first in man administration. No evidence of toxicity has been observed during regulatory toxicity tests on two animal species (rodents and monkeys). Biodistributions on different animal models have shown passive uptake in tumours due to enhanced permeability and retention effect combined with renal elimination of the nanoparticles after intravenous administration. High radiosensitizing effect has been observed with different types of irradiations in vitro and in vivo on a large number of cancer types (brain, lung, melanoma, head and neck…). The review concludes with the second generation of AGuIX nanoparticles and the first preliminary results on human.

show abstract

Section: Radiosensitizationmentioning

confidence: 99%

Section: Radiosensitizationmentioning

confidence: 99%

AGuIX^® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine

Lux

Tran

Thomas

et al. 2018

BJR

110

108

View full text Add to dashboard Cite

show abstract

“…Finally, future investigation should combine reirradiation 3D-IGBT with tumor-specific radio sensitizing agents. Gadolinium-based nanoparticles AGuiX ® are able to specifically penetrate tumors, can act as contrast agents, and are used as a radio-sensitizing agent by locally increasing the energy deposited by the incident radiation [66]. This nanoparticle has been investigated recently in association with radiotherapy in a phase I trial in brain metastasis [67] and a phase I trial is ongoing in locally advanced cervical cancer in association with brachytherapy (NANOCOL, NCT03308604).…”

Section: Discussion and Highlightsmentioning

confidence: 99%

Image-Guided Brachytherapy for Salvage Reirradiation: A Systematic Review

Bockel

Espenel

Sun

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: Local recurrence in gynecological malignancies occurring in a previously irradiated field is a challenging clinical issue. The most frequent curative-intent treatment is salvage surgery. Reirradiation, using three-dimensional image-guided brachytherapy (3D-IGBT), might be a suitable alternative. We reviewed recent literature concerning 3D-IGBT for reirradiation in the context of local recurrences from gynecological malignancies. Methods: We conducted a large-scale literature research, and 15 original studies, responding to our research criteria, were finally selected. Results: Local control rates ranged from 44% to 71.4% at 2–5 years, and overall survival rates ranged from 39.5% to 78% at 2–5 years. Grade ≥3 toxicities ranged from 1.7% to 50%, with only one study reporting a grade 5 event. Results in terms of outcome and toxicities were highly variable depending on studies. Several studies suggested that local control could be improved with 2 Gy equivalent doses >40 Gy. Conclusion: IGBT appears to be a feasible alternative to salvage surgery in inoperable patients or patients refusing surgery, with an acceptable outcome for patients who have no other curative therapeutic options, however at a high cost of long-term grade ≥3 toxicities in some studies. We recommend that patients with local recurrence from gynecologic neoplasm occurring in previously irradiated fields should be referred to highly experienced expert centers. Centralization of data and large-scale multicentric international prospective trials are warranted. Efforts should be made to improve local control while limiting the risk of toxicities.

show abstract

“…Major achievements have been made in the development of polymeric nanoassemblies for cancer theranostics, though most of such nanoassemblies have only been tested in animal models. Among theranostics nanoassemblies under evaluation in humans, the AGuIX nanoassemblies have been applied for tumor radiotherapy . These nanoassemblies are composed of polysiloxane network surrounded by gadolinium(1,4,7,10‐tetra‐azacyclododecane‐1‐glutaric anhydride‐4,7,10‐triacetic acid) (Gd‐DOTA) through covalent binding to the inorganic matrix.…”

Section: Clinical Translation Of Polymeric Nanoassembliesmentioning

confidence: 99%

“…Meanwhile, the Gd‐DOTA inside AGuIX could be applied for cancer imaging by MRI, as Gd‐DOTA is a MRI contrast agent. Thus, AGuIX has been effectively used for MR imaging‐guided radiotherapy of glioma, brain melanoma metastasis, and other tumor models, leading to its evaluation in Phase I trials (ClinicalTrials.gov Identifier: NCT02820454).…”

Section: Clinical Translation Of Polymeric Nanoassembliesmentioning

confidence: 99%

Molecular Cancer Imaging with Polymeric Nanoassemblies: From Tumor Detection to Theranostics

Wang

Nishiyama

et al. 2016

Macromolecular Bioscience

View full text Add to dashboard Cite

Several imaging modalities have been widely applied for the detection of cancer and its pathological activity in combination with probes capable of improving the contrast between healthy and cancerous tissues. Biocompatible polymeric nanoassemblies have been developed for precise detection of malignant tumors by enhancing the selectivity and sensitivity of the imaging. Exploiting the compartmentalized structure of the nanoassemblies advantageously allows delivering both imaging and therapeutic agents for cancer multifunctional imaging and theranostics, i.e., the combination of therapy and diagnosis tool on a single platform. Thus, nanoassemblies have high potential not only for cancer molecular imaging but also for tracing nanoparticles in biological systems, studying their biological pathways, gathering pathological information, monitoring therapeutic effects, and guiding pinpoint therapies. In this review, polymeric nanoassemblies for optical imaging, magnetic resonance imaging, multifunctional imaging, and image-guided therapy, emphasizing their role in cancer diagnosis and theranostics are highlighted.

show abstract

Nanoparticules ultrafines en radiothérapie : le cas des AGuIX

Cited by 9 publications

References 42 publications

AGuIX^® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine

AGuIX^® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine

Image-Guided Brachytherapy for Salvage Reirradiation: A Systematic Review

Molecular Cancer Imaging with Polymeric Nanoassemblies: From Tumor Detection to Theranostics

Contact Info

Product

Resources

About

Nanoparticules ultrafines en radiothérapie : le cas des AGuIX

Cited by 9 publications

References 42 publications

AGuIX® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine

AGuIX® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine

Image-Guided Brachytherapy for Salvage Reirradiation: A Systematic Review

Molecular Cancer Imaging with Polymeric Nanoassemblies: From Tumor Detection to Theranostics

Contact Info

Product

Resources

About

AGuIX^® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine

AGuIX^® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine